Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Cancers Year : 2023

Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas

Abstract

Background: Infections are well known complications of some targeted drugs used to treat solid organ cancer and hematological malignancies. Furthermore, Individual patient risk factors are associated with underlying pathologies, concomitant immunosuppressive treatment, prior treatment and use of anti-infective prophylaxis. Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. Objectives: In this narrative review, we present the current state of knowledge concerning the infectious complications occurring in patients treated with immune checkpoint inhibitors (ICIs), Bruton’s tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, antiapoptotic protein BCL-2 inhibitors, Janus kinase inhibitors or CAR-T cell infusion. Sources: We searched for studies treating infectious complications of ICIs, BTK inhibitors, PI3K inhibitors, antiapoptotic protein BCL-2 inhibitors and CAR-T cell therapy. We included randomized, observational studies and case reports. Content: Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. Treatment of irAEs with corticosteroids and other immunosuppressive agents can lead to opportunistic infections. Bruton’s tyrosine kinase (BTK) inhibitors are associated with higher rate of infections, including invasive fungal infections. Implications: Infections, particularly fungal ones, are common in patients treated with BTK inhibitors even though most of the complications occurring among patients treated by ICIs or CART-cells infusion are associated with the treatment of side effects related to the use of these new treatments. The diagnosis of these infectious complications can be difficult and may require extensive investigations.

Dates and versions

hal-04565223 , version 1 (01-05-2024)

Licence

Identifiers

Cite

Benoît Pilmis, Yousra Kherabi, Pauline Huriez, Jean-Ralph Zahar, Djamel Mokart. Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers, 2023, 15 (7), pp.1989. ⟨10.3390/cancers15071989⟩. ⟨hal-04565223⟩
0 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More